Kodiak Sciences reported successful Phase 3 trial results for its retinal disease treatments Zenkuda and tabirafusp-ted, showing vision improvements comparable to Regeneron's Eylea. Zenkuda allowed 54% of patients to maintain a six-month dosing interval with no intraocular inflammation, highlighting its safety and efficacy. Following the news, Kodiak's stock surged 176% to $89.29, prompting an analyst to raise the price target to $96. This positions Kodiak as a strong competitor in the retinal disease treatment market with potential for further growth.
Kodiak Sciences' recent trial success is context for health sector activity on Pluang. For readers following health stocks, 57 of 100 traded rose while 43 fell. Notable movers include XRAY at USD 9.05 down 3.67%, MESO at USD 14.57 down 3.64%, and TXG at USD 88.64 up 3.42%. Data is as of Sep 29, 2026 01:52 WIB.
The WisdomTree Japan Opportunities Fund ETF (OPPJ) has outperformed major US stock indices in 2024, driven by its focus on industrials and globally diversified Japanese trading firms. However, the fund faces significant challenges due to its over 75%...
Microsoft has introduced new AI-powered tools including Autopilot, Cowork, and Code, which expand its AI capabilities and create new usage-based revenue opportunities. These tools integrate with Office to enhance productivity and allow users to autom...
Gold prices face pressure from rising interest rates and a stronger U.S. dollar, but a strategist from State Street Investment Management believes gold could still reach $4,000 an ounce within a week and potentially $5,000 within six months. The rece...
Shopify has expanded its support for browser-based AI agents by allowing them to complete purchases on merchants' sites, including checkout via Shop Pay. Previously, AI agents could only search products and add items to carts, but now they can inspec...
Trade Desk's stock has fallen 68% this year, underperforming its ad tech peers and the broader tech market. While competitor Magnite's stock rose 46%, Trade Desk and AppLovin, both on the demand side of programmatic advertising, saw sharp declines. T...
